The Effect of a Single Large Dose of Cyclophosphamide on Erythropoiesis and Iron Metabolism in Mice

1974 ◽  
Vol 52 (2) ◽  
pp. 240-247
Author(s):  
Mario Carlos Aggio ◽  
Luis María Fernández ◽  
María Teresa Bruzzo ◽  
Mario Alperin

The effects of a single large dose (350 mg/kg) of cyclophosphamide on erythropoiesis and iron metabolism was studied in BALB/ep mice. These effects include erythropoietic depression lasting 7–10 days followed by a phase of recovery. The depressant action of the drug on erythrocyte production is accompanied by other metabolic effects on iron and hemoglobin metabolism.The erythroid aplasia develops faster and is more profound in spleen than in bone marrow. Radioactive iron injected 8 h after cyclophosphamide is cleared by bone marrow and liver with values above normal and released very slowly. These effects were not observed in the spleen. Differences in iron handling among the diverse sectors of iron stores suggest interference by this drug on the mechanism of hemoglobin breakdown and iron metabolism and an inhomogeneity of the reticuloendothelial system.

Blood ◽  
1966 ◽  
Vol 27 (3) ◽  
pp. 363-370 ◽  
Author(s):  
GEORGE J. FRUHMAN

Abstract Mice injected with a single, large dose of a bacterial endotoxin displayed a significant shift in erythropoiesis from the bone marrow to the spleen. Splenic granulocytopoiesis also occurred. This finding may have some bearing on the observation that endotoxin pretreated mice make a better recovery following x-irradiation than do their controls.


2019 ◽  
Vol 73 ◽  
pp. 359-363
Author(s):  
Małgorzata Ponikowska ◽  
Jacek C. Szepietowski

Iron is an essential microelement in the human body due to its role in hematopoiesis, involvement in energetic processes, synthesis and decomposition of lipids, proteins and nuclear acids. Iron deficiency (ID) is common in healthy populations and also frequently coincides with natural course of chronic diseases. The former is typically present when the overall iron body storages are exhausted (absolute ID), most often due to insufficient iron supply, malabsorption or increased blood loss and coincides with anemia. The latter is a result of defected iron metabolism and reflects a condition, when despite adequate iron stores in the body, iron itself is trapped in the reticuloendothelial system, becoming unavailable for the metabolic processes. It typically occurs in the presence proinflammtory activation in chronic conditions such as chronic kidney disease, inflammatory bowel disorders, malignancies and heart failure. To date there are very few publications concerning the potential role of ID in chronic dermatological disorders. We have recently found that patients with psoriasis demonstrate pattern of ID which can be characterized by negative tissue iron balance with depleted iron stores in the body. Interestingly, presence of ID was not related to the severity of psoriasis, but rather determined by patients low body mass index. We are currently investigating the hypothesis that derangements in iron metabolism resulting in ID can be also present in hidradenitis suppurativa – the other chronic dermatologic disease associated with inflammatory and autoimmune activation.


2021 ◽  
Vol 54 (1) ◽  
pp. 38-46
Author(s):  
Miklós Egyed

Összefoglaló. A humán szervezetnek az alapvető biokémiai reakcióihoz vasra és annak biztonságos használatára van szükség. Emberben vasexcretios út hiányában a vasanyagcsere sarkalatos pontja a duodenális absorptio, amelyet a májsejtek által termelt hormon, a hepcidin szabályoz. A hepcidin a ferroportin lisosomalis degradációját okozva blokkolja a vasnak a vérbe való belépését a duodenális enterocytából, a reticuloendothelialis rendszer (RES) macrophagokból és a májsejtekből. A reguláló hormon képzését a szervezet vaskészlete mellett az erythropoiesis, hypoxia és inflammatorikus folyamatok befolyásolják. A szabályozás kóros eltérései vashiány vagy vasterhelés útján súlyos betegségeket okozhatnak. A hepcidin képződését befolyásoló folyamatokat illetően ismereteink jelentősen gyarapodtak, közleményünk célja ezek bemutatása. Summary. The basic biochemical reactions of the human body require iron and its safe utilisation. In absence of an iron-excreation pathway in human, the pivotal point of iron metabolism is duodenal absorption, which is regulated by a hormone produced by liver cells, the hepcidin. Causing lisosomal degradation of ferroportin, hepcidin blocks the iron entry into the blood from duodenal enterocytes, reticuloendothelial system (RES) macrophages, and liver cells. In addition to the body’s iron stores, the production of the regulatory hormone is also affected by erythropoiesis, hypoxia and inflammatory processes. Abnormal regulation can lead to serious illness through iron deficiency or iron stress. Regarding the processes influencing the formation of hepcidin, our knowledge has significantly increased and the aim of our paper is to present them.


Blood ◽  
1974 ◽  
Vol 43 (2) ◽  
pp. 291-295 ◽  
Author(s):  
M. A. M. Ali ◽  
G. Sweeney

Abstract Sideroblastic erythropoiesis is a recognized complication of acute alcoholism1 and disturbances in porphyrin synthesis have been reported in sideroblastic anemia2. In order to investigate the mechanism of alcoholic-induced sideroblastic erythropoiesis coproporphyrin (C.P.) and protoporphyrin (P.P.) levels were measured in 26 patients admitted with acute alcoholism. Bone marrow examination showed that 11 patients had ring sideroblasts, while in 15 other patients there were adequate iron stores, but no ring sideroblasts. The red blood cell (C.P.) and (P.P.) levels were elevated in all of the 11 patients with ring sideroblasts, but in only three out of the 15 patients with no ring sideroblasts. These data clearly separate those patients with a disturbance of mitochondrial iron metabolism and increased erythrocyte porphyrins from other patients suffering from a comparable degree of alcoholism in whom neither abnormality appeared to exist. We conclude therefore that alcoholic sideroblastic erythropoiesis probably reflects ethanol-induced disturbance in the heme synthetic pathway.


1977 ◽  
Vol 15 (23) ◽  
pp. 92-92

Depressed patients tend to be forgetful, and for them a simple dosage regimen is particularly appropriate. The use of a single daily dosage depends on the drug having a relatively long (over 36 hours) half-life in the body and being tolerated in a single large dose. Many tricyclic anti-depressives fulfil these requirements provided that the single dose is given before the patient goes to bed. Unwanted effects such as dry mouth and blurred vision, which are troublesome during the day, are not a problem during sleep. The sedative actions of many of these drugs can help the insomniac depressed patient who might otherwise need a separate hypnotic.


1966 ◽  
Vol 4 (3) ◽  
pp. 9-11

We have discussed iron preparations for adults in earlier articles;1 much of the information applies equally to children. Iron is not a ‘tonic’ and should be given only to prevent or correct iron deficiency. Estimation of the haemoglobin and inspection of a blood smear are the minimum investigations necessary before iron is prescribed in therapy. When deficiency is suspected in the absence of hypochromic anaemia, plasma iron and iron-binding capacity should be estimated and/or the bone marrow examined for haemosiderin crystals which disappear when iron stores are depleted.


Blood ◽  
2017 ◽  
Vol 130 (Suppl_1) ◽  
pp. 79-79
Author(s):  
Andrew Crispin ◽  
Paul Schmidt ◽  
Dean Campagna ◽  
Chang Cao ◽  
Daniel Lichtenstein ◽  
...  

Abstract Congenital sideroblastic anemias (CSAs) are uncommon inherited diseases resulting from defects in heme biosynthesis, mitochondrial translation or mitochondrial iron-sulfur cluster (ISC) assembly. CSAs are characterized by pathological mitochondrial iron deposits in bone marrow erythroblasts. Recently, mutations in mitochondrialheat shock protein 70 (HSPA9), a critical chaperone involved in mitochondrial ISC assembly, have been reported as a cause of non-syndromic CSA. Human heat shock cognate protein 20 (HSCB), a highly conserved mitochondrial co-chaperone, is the primary binding partner of HSPA9. HSCB allows the transfer of nascent ISC to HSPA9 and stimulates its ATPase activity, promoting ISC transfer to target proteins. To identify novel genes responsible for CSA, we performed whole exome sequencing on more than 75 CSA probands and their family members. In one patient, a young woman, with pancytopenia characterized by a normocytic anemia with numerous bone marrow ringed sideroblasts, we identified two variants in HSCB : a paternally-inherited promoter variant (c.-134C>A) predicted to disrupt a conserved ETS transcription factor binding site, and a maternally-inherited frameshift (c.259dup, p.T87fs*27). A fibroblast cell-line derived from the proband showed a decrease in HSCB expression, but normal HSPA9 expression compared to healthy, unrelated controls. Impairment of ETS1-dependent transcriptional activation of the promoter variant was demonstrated in K562 cells transfected with an HSCB-luciferase reporter construct. K562 cells were also employed to determine if reduced expression of HSCB could result in impaired erythroid metabolism, maturation, or proliferation. K562 cells infected with shRNA directed against HSCB were deficient in multiple mitochondrial respiratory complexes, had abnormal iron metabolism and a defect of protein lipoylation, all consistent with defective ISC metabolism. In addition, both IRP1 and IRP2 expression were decreased and cell surface transferrin receptor 1 (TFR1) expression was enhanced, suggesting disturbed cellular iron metabolism. Nevertheless, cells lacking HSCB partially retained an ability to respond to iron chelation and iron overload. Cells lacking HSCB lose their ability to hemoglobinize in response to sodium butyrate treatment (Figure 1A). This defect was confirmed in vivo using a morpholino strategy in zebrafish, as fish lacking HSCB are also unable to hemoglobize (Fig 1B). We generated an Hscb conditional mouse to better elucidate the underlying pathophysiology of the disease. Heterozygous (Hscb+/-) animals have no discernable phenotype; however, null animals die prior to embryonic day E7.5. Thus, to avoid this lethality, we employed Vav-cre animals (Tg(Vav1-cre)1Graf) to evaluate the loss of HSCB specifically in the hematopoietic compartment. Hscbc/- Vav-cre+ pups are pale and growth retarded compared to control littermates and die at approximately p10 with severe pancytopenia. To assess the loss of HSCB specifically in the erythroid lineage, we bred conditional animals to EpoR-cre (Eportm1(EGFP/cre)Uk) mice. Hscbc/- EpoR-cre+ mice die at approximately E12.5 due to a complete failure of erythropoiesis (Figure 1C). Finally, temporally inducible, hematopoietic-specific deletion animals were generated by transplantation of fetal livers from Mx-Cre (Tg(Mx1-cre)1Cgn) positive Hscbc/- animals. After polyinosinic:polycytidylic acid (pIpC) induction, global defects of hematopoiesis were observed in Mx-Cre+ animals, leading to their death 3-weeks post-induction from profound pancytopenia. A transient siderocytosis was seen in the peripheral blood between days 6-8 post-pIpC. Flow cytometry using FSC-TER119-CD44 gating strategy confirmed the defect in erythropoiesis. Taken together, these data demonstrate that HSCB is essential for hematopoiesis; both whole animal and in vitro cell culture models recapitulate the patient's phenotype, suggesting that the two patient mutations are likely disease-causing. Figure 1 Figure 1. Disclosures No relevant conflicts of interest to declare.


Sign in / Sign up

Export Citation Format

Share Document